Are SOFT and TEXT results practice changing and how?
Optimal adjuvant endocrine therapy for premenopausal women with hormone-receptor positive breast cancer has long been debated. In particular, the role of ovarian function suppression in addition to standard tamoxifen divided oncologists worldwide, and more recently, the role of aromatase inhibitors as an alternative to tamoxifen in the setting of ovarian suppression became a key question. In 2014, the long awaited results of the International Breast Cancer Study Group (IBCSG) led randomized, phase 3 trials, Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT), provided additional evidence to inform the discussion. The interpretation of the SOFT and TEXT trial data can facilitate better selection of appropriate endocrine therapy according to individual disease characteristics, recognizing the complexity of the puzzle, which is still not complete.
Institute of Oncology and Breast Unit of Southern Switzerland, Bellinzona, Switzerland; International Breast Cancer Study Group, Bern, Switzerland. Electronic address: olivia.pagani@ibcsg.org.
Olivia
O
Pagani
International Breast Cancer Study Group, Bern, Switzerland; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Meredith M
MM
Regan
International Breast Cancer Study Group, Bern, Switzerland; Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Australia; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle, Australia.
Prudence A
PA
Francis
D000328:Adult; D000730:Androstadienes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D010053:Ovary / Q000187:drug effects; D017697:Premenopause; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use*
D000730:Androstadienes; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; C508053:ERBB2 protein, human; C056516:exemestane
Breast cancer; Endocrine therapy; Exemestane; Ovarian suppression; Premenopausal; Tamoxifen